We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prevention of Decompensation in Liver Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00239096
Recruitment Status : Unknown
Verified October 2005 by Odense University Hospital.
Recruitment status was:  Recruiting
First Posted : October 14, 2005
Last Update Posted : October 14, 2005
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention. Moreover is the purpose to asses whether losartan is antifibrotic.

Condition or disease Intervention/treatment Phase
Alcoholic Liver Cirrhosis Ascites Drug: losartan (drug) Phase 4

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study
Study Start Date : September 2005
Estimated Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Death

Secondary Outcome Measures :
  1. varices
  2. need for therapeutic ascites drainage
  3. gastrointestinal bleeding episodes

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The presence of cirrhosis in a liver biopsy; or, in the absence of histology, clinical and laboratory evidence of cirrhosis combined with years of excessive alcohol intake.

Age 18-70 years

Exclusion Criteria:

  1. Cirrhosis due to alpha1-antitrypsin deficiency, viral hepatitis or autoimmunity.
  2. Renal disease evidenced by proteinuria > 0,5 g/day.
  3. Heart disease
  4. Hypertension
  5. Cancer or disease other than cirrhosis expected to limit life expectancy to < 5 years.
  6. Pregnancy or lactation
  7. Sepsis within 5 days
  8. Gastrointestinal bleeding within 5 days
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00239096

Contact: Ove B. Schaffalitzky de Muckadell, Professor 0045 65412750 sdm@ouh.fyns-amt.dk

Odense University Hospital Recruiting
Odense, Denmark, 5000
Contact: Ove B Schaffalitzky de Muckadell, Professor    0045 65412750    sdm@ouh.fyns-amt.dk   
Principal Investigator: Annette Dam, MD         
Sponsors and Collaborators
Odense University Hospital
Lundbeck Foundation
University of Southern Denmark
Else Poulsen Mindelegat
Principal Investigator: Annette Dam, MD
More Information

ClinicalTrials.gov Identifier: NCT00239096     History of Changes
Other Study ID Numbers: VF20040245
Eudra CT: 2005-001191-12
First Posted: October 14, 2005    Key Record Dates
Last Update Posted: October 14, 2005
Last Verified: October 2005

Keywords provided by Odense University Hospital:
alcoholic liver cirrhosis
sodium retention

Additional relevant MeSH terms:
Liver Cirrhosis
Liver Cirrhosis, Alcoholic
Pathologic Processes
Liver Diseases
Digestive System Diseases
Liver Diseases, Alcoholic
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action